TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32962743

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study: 35367136

Group type: EXPERIMENTAL
Intervention: Mixed allergenic food powder (MP) containing egg, milk, wheat, soybean, buckwheat, and peanuts, administered in increasing amounts until week 12
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo powder (PP)
Number of subjects: 163
Study: 33766017

Group type: EXPERIMENTAL
Intervention: MyFood decision support system
Number of subjects: 100
Study: 36290823

Group type: EXPERIMENTAL
Intervention: Nutritional counseling provided by registered dietitians at least every two weeks during antineoplastic treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no nutritional counseling)
Number of subjects: 61
Study: 34167705

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation body massager type A (two small pads)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation body massager type B (one large pad)
Number of subjects: 20
Study: 34953531

Group type: EXPERIMENTAL
Intervention: Oral octreotide (40 mg a day, optional titration to 60 or 80 mg a day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Injectable somatostatin receptor ligands (iSRLs) at the same dose and interval as before enrolment
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oral octreotide
Number of subjects: 92

Group type: COMPARATOR
Intervention: Injectable somatostatin receptor ligands (iSRLs)
Number of subjects: 92
Study: 32171169

Group type: EXPERIMENTAL
Intervention: Contralateral strength training (CST)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Direct strength training (DST)
Number of subjects: 28
Study: 32931725

Group type: EXPERIMENTAL
Intervention: Chemicals
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Aerosol
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Perceived harm of secondhand e‐cigarette exposure
Number of subjects: 791
Study: 32071129

Group type: EXPERIMENTAL
Intervention: Nasal aspiration
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal suctioning
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both suctioning techniques
Number of subjects: 16
Study: 34382434

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33038338

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 30
Study: 36226327

Group type: EXPERIMENTAL
Intervention: Observational trial
Number of subjects: 17

Group type: COMPARATOR
Intervention: Randomized trial
Number of subjects: 17
Study: 33612449

Group type: EXPERIMENTAL
Intervention: Antifibrinolytics and plasma products (including intravenous immunoglobulin)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: HLA matched products (Grade A or B1U)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bleeding-related mortality
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clinically relevant bleeding (by ISTH criteria)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hemorrhagic shock
Number of subjects: 51
Study: 32822076

Group type: EXPERIMENTAL
Intervention: Finger flexors (FFs)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ankle plantar flexors (PFs)
Number of subjects: 32
Study: 35093278

Group type: EXPERIMENTAL
Intervention: MitraClip treatment
Number of subjects: 614

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study: 33536271

Group type: EXPERIMENTAL
Intervention: Low-dose alteplase
Number of subjects: 490

Group type: COMPARATOR
Intervention: Standard-dose alteplase
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Low-dose vs Standard-dose alteplase
Number of subjects: 490
Study: 35398218

Group type: EXPERIMENTAL
Intervention: PF-06826647 200 mg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PF-06826647 400 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: PF-06826647
Number of subjects: 178
Study: 32772474

Group type: EXPERIMENTAL
Intervention: MarginProbe device
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard intraoperative assessments (Control)
Number of subjects: 46
Study: 34261093

Group type: EXPERIMENTAL
Intervention: Long-acting therapy (cabotegravir with rilpivirine, dosed every 4 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Switch arm (transition from current antiretroviral therapy to long-acting therapy)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Long-acting therapy (cabotegravir with rilpivirine)
Number of subjects: 52
Study: 33078655

Group type: EXPERIMENTAL
Intervention: Healthy Families America (HFA) program
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Prenatal care and coordination (PNCC) program
Number of subjects: 139

Group type: COMPARATOR
Intervention: Comparison group (quasi-experimental group)
Number of subjects: 139
Study: 32925908

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adipose tissue characteristics (adipose MT gene expression, body fat percent, adipose cell types)
Number of subjects: 0
Study: 35183744

Group type: EXPERIMENTAL
Intervention: Topical pHisoHex (hexachlorophene [1% triclosan; sodium benzoate, 5 mg/mL; and benzyl alcohol, 5 mg/mL])
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 5% Benzoyl Peroxide (BPO)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 5% Benzoyl Peroxide with 1% Clindamycin (BPO-C)
Number of subjects: 101
Study: 33556935

Group type: EXPERIMENTAL
Intervention: Intensive weight-loss lifestyle intervention with an energy-reduced Mediterranean diet (erMedDiet), physical activity promotion, and behavioral support
Number of subjects: 6719

Group type: COMPARATOR
Intervention: Usual-care advice to adhere to an energy-unrestricted Mediterranean diet
Number of subjects: 6719

Group type: EXPERIMENTAL
Intervention: Intensive weight-loss lifestyle intervention with an energy-reduced Mediterranean diet (erMedDiet)
Number of subjects: 6719
Study: 32838763

Group type: EXPERIMENTAL
Intervention: col-ACP intervention (6 sessions)
Number of subjects: 270

Group type: COMPARATOR
Intervention: supportive intervention (active control group)
Number of subjects: 270

Group type: COMPARATOR
Intervention: standard medical care (TAU)
Number of subjects: 270
Study: 35060759

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) intervention, 8 weeks duration, 2 times per week, guided strength exercises with landing stabilization focus.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard of care, no recommendations provided.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NMT intervention
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NMT intervention and standard of care
Number of subjects: 27
Study: 34329963

Group type: EXPERIMENTAL
Intervention: Double scenario simulations
Number of subjects: 146

Group type: COMPARATOR
Intervention: Single scenario simulations
Number of subjects: 146
Study: 32122284

Group type: EXPERIMENTAL
Intervention: Racial exclusion (vs. inclusion)
Number of subjects: 276
Study: 35834198

Group type: EXPERIMENTAL
Intervention: Augmented Reality smoking cues (extinction condition)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Augmented Reality neutral cues (control condition)
Number of subjects: 129
Study: 33470595

Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty (RSA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Visual analog scale for pain, DASH scores, SF‐12 scores, radiographic outcomes
Number of subjects: 31
Study: 34363558

Group type: EXPERIMENTAL
Intervention: gilteritinib (120 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: salvage chemotherapy (SC)
Number of subjects: 48
Study: 35410211

Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL) in bedside teaching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional bedside teaching
Number of subjects: 30
Study: 32164886

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg daily or maximum tolerated dose up to 1.8 mg daily)
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo plus standard care
Number of subjects: 9340
Study: 34143186

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (Amoxicillin & Clavulanic Acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32696304

Group type: EXPERIMENTAL
Intervention: Phone calls and assistance scheduling mammograms
Number of subjects: 890

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 890
Study: 35297744

Group type: EXPERIMENTAL
Intervention: BOLSTER intervention (10-week duration)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BOLSTER intervention (4-week duration)
Number of subjects: 15
Study: 33215895

Group type: EXPERIMENTAL
Intervention: Global Trigger Tool (GTT)
Number of subjects: 120
Study: 33771205

Group type: EXPERIMENTAL
Intervention: GV1001 1.12 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: GV1001 0.56 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 35063242

Group type: EXPERIMENTAL
Intervention: Cornelian cherry fruit extract (20 cc/d for 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (20 cc/d for 12 weeks)
Number of subjects: 50
Study: 33109935

Group type: EXPERIMENTAL
Intervention: Intervention participants received an individualized linkage plan and minibooster sessions.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control participants received treatment as usual.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Intervention participants were linked to PrEP care significantly sooner than control participants.
Number of subjects: 146
Study: 32622610

Group type: EXPERIMENTAL
Intervention: Colostrum feeding (CF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mixture of 50% colostrum and 50% whole milk
Number of subjects: 24

Group type: COMPARATOR
Intervention: Whole milk
Number of subjects: 24
Study: 36266930

Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching (OPC) - eight weekly sessions
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual self-care education
Number of subjects: 44
Study: 34848584

Group type: EXPERIMENTAL
Intervention: TDF/FTC+DTG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAF/FTC+DTG
Number of subjects: 0

Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 0
Study: 35606886

Group type: EXPERIMENTAL
Intervention: TF‐CBTp + treatment as usual (TAU)
Number of subjects: 300

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 300
Study: 33788296

Group type: EXPERIMENTAL
Intervention: MD+LPS (5 mg/kg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control+LPS (5 mg/kg)
Number of subjects: 4
Study: 32134851

Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35606010

Group type: EXPERIMENTAL
Intervention: Molnupiravir, a novel antiviral medicine aimed at reducing the ability of SARS-CoV-2 to multiply in the body.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care for COVID-19 patients as provided by the National Health Service in England.
Number of subjects: 0
Study: 35842120

Group type: EXPERIMENTAL
Intervention: Hydronidone 180 mg/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Hydronidone 270 mg/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Hydronidone 360 mg/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Combined hydronidone group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 32949315

Group type: EXPERIMENTAL
Intervention: NPDC program model
Number of subjects: 486

Group type: COMPARATOR
Intervention: SAU (services as usual)
Number of subjects: 486
Study: 32723349

Group type: EXPERIMENTAL
Intervention: AWARE risk reduction program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study: 36089558

Group type: EXPERIMENTAL
Intervention: Buzzy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Cold spray
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Buzzy and cold spray
Number of subjects: 161
Study: 33230607

Group type: EXPERIMENTAL
Intervention: Photo group (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-photo group (n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 36113906

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (ImRs), 16 sessions; n = 21
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Skills training in Affective and Interpersonal Regulation (STAIR) followed by ImRs, 8 STAIR sessions followed by 16 ImRs sessions; n = 20
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist, 8 weeks; n = 20
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ImRs (after waitlist completion), total n for this condition = 30
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: STAIR/ImRs (after waitlist completion), total n for this condition = 31
Number of subjects: 61
Study: 32598568

Group type: EXPERIMENTAL
Intervention: DHAV-1 infection in non-embryonated eggs
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DHAV-1 infection in 17-day-old embryos
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DHAV-1 infection in dead embryos
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DHAV-1 infection in newly hatched ducklings
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall detection of DHAV-1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pathogenicity of DHAV-1 isolates
Number of subjects: 90
Study: 35312941

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 35308141

Group type: EXPERIMENTAL
Intervention: Neurology nursing (SG)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine nursing (CG)
Number of subjects: 110
Study: 34726849

Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing followed by application of sponge floss
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control treatments (sponge floss only, ultrasonic device with polyetheretherketone fibre tip coating, and manual scaling with carbon fibre curettes and use of sponge floss)
Number of subjects: 85
Study: 35337306

Group type: EXPERIMENTAL
Intervention: All-inside ACLR
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard ACLR
Number of subjects: 54
Study: 33467641

Group type: EXPERIMENTAL
Intervention: HIIT and nutrition intervention (school-based program)
Number of subjects: 48
Study: 34130550

Group type: EXPERIMENTAL
Intervention: ω‐3 fish oil (3200 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 30
Study: 32889959

Group type: EXPERIMENTAL
Intervention: Bioenhanced curcumin (BEC) 50 mg twice daily
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 36196673

Group type: EXPERIMENTAL
Intervention: Psychological resilience
Number of subjects: 3199
Study: 34355337

Group type: EXPERIMENTAL
Intervention: Antral resection sleeve gastrectomy (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antral preservation sleeve gastrectomy (Group B)
Number of subjects: 36
Study: 32575441

Group type: EXPERIMENTAL
Intervention: Pomegranate extract 20 mL (720 mg phenolic compounds) for two weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 18
Study: 35729622

Group type: EXPERIMENTAL
Intervention: Motivational interview counseling
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Text messaging grounded in behavioral economics
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Access to testing (via navigation to an appointment vs. a self-test kit)
Number of subjects: 448
Study: 34154490

Group type: EXPERIMENTAL
Intervention: Abdominal Binder (AB)
Number of subjects: 346
Study: 32349413

Group type: EXPERIMENTAL
Intervention: VR-based training program (30 min/day, 2 days/week for 3 months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 35761219

Group type: EXPERIMENTAL
Intervention: Convalescent plasma plus standard therapy (CP + ST)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard therapy alone (ST)
Number of subjects: 101
Study: 33394545

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS) including achieving ≥7% weight loss, ≥150 min/wk of moderate leisure-time physical activity, and/or a goal for self-reported total fat intake.
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Achievement of the weight loss goal.
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Achievement of the physical activity goal.
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Achievement of the diet goal.
Number of subjects: 823
Study: 32183736

Group type: EXPERIMENTAL
Intervention: Neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC
Number of subjects: 326

Group type: COMPARATOR
Intervention: Standard R0 D2 followed by 8 cycles of adjuvant chemotherapy (AC) with oxaliplatin and S-1 (SOX) regimen
Number of subjects: 326
Study: 34327732

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (2400 mg over 5 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33347002

Group type: EXPERIMENTAL
Intervention: Prabotulinum toxin A (24 units)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prabotulinum toxin A (48 units)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prabotulinum toxin A (72 units)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prabotulinum toxin A (96 units)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study: 34787823

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.5 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Weekly dulaglutide doses for 4 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 34091608

Group type: EXPERIMENTAL
Intervention: Antibiotics plus bronchoscopic suction every other day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics with daily closed-suction
Number of subjects: 0
Study: 32998911

Group type: EXPERIMENTAL
Intervention: Audible signs of respiratory dysfunction (inspiratory stridor, expiratory wheeze, combined stridor+wheeze, cough)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Follow-up clinical workup for EIA
Number of subjects: 48
Study: 33514329

Group type: EXPERIMENTAL
Intervention: VIVIFRAIL© multicomponent exercise program performed five times a week (2 times supervised, 3 times home-based) for 12 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: VIVIFRAIL© multicomponent exercise program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Health education meetings
Number of subjects: 44
Study: 33146438

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) cycling, goal‐directed training, and adapted cycling
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21
Study: 32660791

Group type: EXPERIMENTAL
Intervention: Increased fried food consumption
Number of subjects: 2043

Group type: EXPERIMENTAL
Intervention: Replacing 100 g/day of fried food with non-fried food
Number of subjects: 2043

Group type: EXPERIMENTAL
Intervention: Replacing 100 g/day of fried protein-rich food
Number of subjects: 2043

Group type: EXPERIMENTAL
Intervention: Replacing 100 g/day of fried eggs
Number of subjects: 2043

Group type: EXPERIMENTAL
Intervention: Replacing 100 g/day of fried fish
Number of subjects: 2043

Group type: EXPERIMENTAL
Intervention: Increased olive oil intake
Number of subjects: 2043

Group type: EXPERIMENTAL
Intervention: Olive oil with non-fried food
Number of subjects: 2043
Study: 32992642

Group type: EXPERIMENTAL
Intervention: Intermittent Epidural Bolus (IEB)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI)
Number of subjects: 938
Study: 35488883

Group type: EXPERIMENTAL
Intervention: Single-visit root canal retreatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Two-visit root canal retreatment (control)
Number of subjects: 100
Study: 34343658

Group type: EXPERIMENTAL
Intervention: Daratumumab (Dara) with or without standard chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy (as a control)
Number of subjects: 0
Study: 32018062

Group type: EXPERIMENTAL
Intervention: Remestemcel-L therapy (2 × 10^6 cells/kg twice weekly for 4 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Remestemcel-L therapy
Number of subjects: 54
Study: 33840074

Group type: EXPERIMENTAL
Intervention: Impulsivity (measured by I-8 subscales)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Maladaptive personality traits (measured by PID-5 subscales)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Interactions between personality traits and impulsivity
Number of subjects: 519
Study: 34142740

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) preconditioning for 30 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (40-min seated-rest)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Exercise (30-min seated-rest followed by 150 knee-squats)
Number of subjects: 8
Study: 36103288

Group type: EXPERIMENTAL
Intervention: Dermolina-Henna cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mometasone cream
Number of subjects: 0
Study: 36235569

Group type: EXPERIMENTAL
Intervention: BSG extract-based food supplement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 34160184

Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Nutrition (PBN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60